Compare Citius Pharmaceuticals Inc (CTXR) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs General Motors Company — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while General Motors Company trades at $82.84 (market cap $72.17B). The key difference: General Motors Company is far larger — about 5298.8× Citius Pharmaceuticals Inc's market cap, and General Motors Company pays a 0.88% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and General Motors Company for 83 Days on average.
| CTXR | GM | |
|---|---|---|
Market Cap | $13.62M | $72.17B |
Volume | 132,438 | 4,900,304 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $90.30 |
52-Week Low | $0.48 | $55.35 |
Typical Hold Time | 17 Days | 83 Days |
Enterprise Value | $3.79M | $175.15B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
General Motors (GM) trades at $82.34, up 1.67% with recent earnings beats but faces bearish technical signals. The company reported declining Q3 2026 vehicle sales of 5.5% amid EV market challenges, while maintaining strong cash flow from operations at $26.87B in 2025. Valuation metrics show a P/E of 36.72 and P/S of 0.42, with analyst consensus favoring a Buy rating and $102.08 price target.
GM's outlook is mixed with solid fundamentals offset by near-term headwinds. Investment opportunities include potential regulatory savings of $20.4B from eased fuel economy rules and consistent earnings outperformance. Key risks involve competitive pressure from Asian automakers, declining market share, and profitability pressures with net margins at 1.05%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
